Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-06-28
DOI
10.3389/fphar.2021.696960
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ABCB1, ABCG2, ABCC1, ABCC2 and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
- (2021) Henrike Bruckmueller et al. Expert Opinion on Drug Metabolism & Toxicology
- Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future
- (2021) Valentina R. Minciacchi et al. Cells
- European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
- (2020) A. Hochhaus et al. LEUKEMIA
- Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
- (2020) Denis L. Jardim et al. OncoImmunology
- Response and Resistance to BCR-ABL1-Targeted Therapies
- (2020) Theodore P. Braun et al. CANCER CELL
- The multi‐tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real‐world data
- (2020) Luigia Luciano et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Effect of the Most Relevant CYP3A4 and CYP3A5 Polymorphisms on the Pharmacokinetic Parameters of 10 CYP3A Substrates
- (2020) Miriam Saiz-Rodríguez et al. Biomedicines
- Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 signaling pathways critical for development of therapy resistance
- (2020) Theresa Klümper et al. Experimental Hematology & Oncology
- Proposed diagnostic criteria for classical CMML, CMML variants and pre-CMML conditions
- (2019) Peter Valent et al. HAEMATOLOGICA
- Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
- (2019) Simona Soverini et al. Journal of Hematology & Oncology
- Cancer Cell Lines Are Useful Model Systems for Medical Research
- (2019) Mirabelli et al. Cancers
- Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants
- (2019) Christopher A. Eide et al. CANCER CELL
- Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
- (2019) Timothy P. Hughes et al. BLOOD
- Alternative polyadenylation of ABC-transporters of the C-family (ABCC1, ABCC2, ABCC3) and implications on post-transcriptional micro-RNA regulation
- (2019) Oliver Bruhn et al. MOLECULAR PHARMACOLOGY
- Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
- (2019) Timothy P. Hughes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR
- (2018) Imran Shair Mohammad et al. BIOMEDICINE & PHARMACOTHERAPY
- A method of gene expression data transfer from cell lines to cancer patients for machine-learning prediction of drug efficiency
- (2018) Nicolas Borisov et al. CELL CYCLE
- Effect of ABCG2 , OCT1 , and ABCB1 ( MDR1 ) Gene Expression on Treatment-Free Remission in a EURO-SKI Subtrial
- (2018) Sébastien Rinaldetti et al. Clinical Lymphoma Myeloma & Leukemia
- Inter-individual variation in imatinib disposition: any role for prevalent variants of CYP1A2, CYP2C8, CYP2C9, and CYP3A5 in Nigerian CML patients?
- (2018) Ayorinde Adehin et al. LEUKEMIA & LYMPHOMA
- Advances in studies of tyrosine kinase inhibitors and their acquired resistance
- (2018) Qinlian Jiao et al. Molecular Cancer
- Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis
- (2018) Sarah Cargnin et al. PHARMACOLOGICAL RESEARCH
- Melanoma and Immune Checkpoint Inhibitors
- (2018) Masutaka Furue et al. Current Oncology Reports
- Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor
- (2018) Xianbin Tian et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
- (2018) Joseph Schoepfer et al. JOURNAL OF MEDICINAL CHEMISTRY
- Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis
- (2017) Leonardo Campiotti et al. EUROPEAN JOURNAL OF CANCER
- Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents
- (2017) Giovanni Luca Beretta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia
- (2017) Gabriel Etienne et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
- (2017) Andreas Hochhaus et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis
- (2017) Zhi-Ping Jiang et al. PHARMACOGENOMICS
- Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia
- (2017) Natarajan Harivenkatesh et al. PHARMACOLOGICAL RESEARCH
- The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia
- (2017) Sara Galimberti et al. Oncotarget
- MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells
- (2017) Meike Kaehler et al. Oncotarget
- Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin
- (2017) S Osorio et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib
- (2016) Ferdows Atiq et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
- (2016) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
- (2016) G Heller et al. LEUKEMIA
- European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
- (2016) J L Steegmann et al. LEUKEMIA
- miRNAs in chronic myeloid leukemia: small molecules, essential function
- (2016) Zofia Litwińska et al. LEUKEMIA & LYMPHOMA
- Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?
- (2016) Gianantonio Rosti et al. Nature Reviews Clinical Oncology
- Length variants of the ABCB1 3′-UTR and loss of miRNA binding sites: possible consequences in regulation and pharmacotherapy resistance
- (2016) Oliver Bruhn et al. PHARMACOGENOMICS
- ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib
- (2016) Géraldine Dessilly et al. PHARMACOGENOMICS
- Impact of ABCB1 1236C > T-2677G > T-3435C > T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib
- (2016) Géraldine Dessilly et al. Scientific Reports
- Multidrug resistance gene (MDR1) polymorphisms may not be directly associated with response to imatinib in chronic myeloid leukemia
- (2015) J.L. Wang et al. GENETICS AND MOLECULAR RESEARCH
- OCT1 and imatinib transport in CML: is it clinically relevant?
- (2015) D B Watkins et al. LEUKEMIA
- Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV
- (2015) L Kalmanti et al. LEUKEMIA
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
- (2014) Matthew S. Zabriskie et al. CANCER CELL
- Functional Gene Variants of CYP3A4
- (2014) A N Werk et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance
- (2014) Oliver Bruhn et al. Expert Opinion on Drug Metabolism & Toxicology
- Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance
- (2014) Nagaraju Anreddy et al. MOLECULES
- ABC Transporters in Multi-Drug Resistance and ADME-Tox of Small Molecule Tyrosine Kinase Inhibitors
- (2014) Jiexin Deng et al. PHARMACEUTICAL RESEARCH
- In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies
- (2014) Martina McDermott et al. Frontiers in Oncology
- Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?
- (2013) Vivian M. Rumjanek et al. BIOSCIENCE REPORTS
- European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
- (2013) M. Baccarani et al. BLOOD
- Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the fr
- (2013) Simona Soverini et al. CANCER
- Cellular Uptake of Imatinib into Leukemic Cells Is Independent of Human Organic Cation Transporter 1 (OCT1)
- (2013) A. T. Nies et al. CLINICAL CANCER RESEARCH
- Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
- (2013) Ahmed M.L. Bedewy et al. Hematology
- Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia
- (2013) Yue Liu et al. LEUKEMIA RESEARCH
- Imatinib induces demethylation of miR-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib
- (2013) Tatsuki Shibuta et al. LEUKEMIA RESEARCH
- Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors
- (2013) Jing Gao et al. MEDICAL ONCOLOGY
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
- (2013) J.E. Cortes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line
- (2013) Karin Skoglund et al. Pharmacogenetics and Genomics
- Role of Epigenetics in Chronic Myeloid Leukemia
- (2013) Katerina Machova Polakova et al. Current Hematologic Malignancy Reports
- Myc induced miR-144/451 contributes to the acquired imatinib resistance in chronic myelogenous leukemia cell K562
- (2012) Li Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Therapy for metastatic melanoma: the past, present, and future
- (2012) Laura Finn et al. BMC Medicine
- Activity-based kinase profiling of approved tyrosine kinase inhibitors
- (2012) Daisuke Kitagawa et al. GENES TO CELLS
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors
- (2012) Susumu Kobayashi et al. Journal of Thoracic Oncology
- Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
- (2012) Laura N. Eadie et al. LEUKEMIA & LYMPHOMA
- MicroRNA profiling in K-562 cells under imatinib treatment
- (2012) Eleonora Turrini et al. Pharmacogenetics and Genomics
- Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells
- (2011) Petr Mlejnek et al. ANNALS OF HEMATOLOGY
- Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates
- (2011) AM Filppula et al. BRITISH JOURNAL OF PHARMACOLOGY
- Molecular Pathways: BCR-ABL
- (2011) D. Cilloni et al. CLINICAL CANCER RESEARCH
- Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
- (2011) Matthias Scheffler et al. CLINICAL PHARMACOKINETICS
- Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors
- (2011) Paola Di Gion et al. CLINICAL PHARMACOKINETICS
- Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment
- (2011) Elias Jabbour et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1
- (2011) Marta Gromicho et al. LEUKEMIA & LYMPHOMA
- Expression patterns of microRNAs associated with CML phases and their disease related targets
- (2011) Kateřina Machová Poláková et al. Molecular Cancer
- Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia
- (2011) Jaroslav Jelinek et al. PLoS One
- Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
- (2010) A. Haouala et al. BLOOD
- CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity
- (2010) Henrik Gréen et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia
- (2010) S. Flamant et al. HAEMATOLOGICA
- Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia
- (2010) Naoto Takahashi et al. JOURNAL OF HUMAN GENETICS
- Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 Activity
- (2010) J R Engler et al. LEUKEMIA
- Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia
- (2010) D Bixby et al. LEUKEMIA
- Extended kinase profile and properties of the protein kinase inhibitor nilotinib
- (2009) Paul W. Manley et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
- (2009) G. Rosti et al. BLOOD
- Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties
- (2009) C Hegedűs et al. BRITISH JOURNAL OF PHARMACOLOGY
- Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia
- (2009) D. Milojkovic et al. CLINICAL CANCER RESEARCH
- Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia
- (2009) D. H. Kim et al. CLINICAL CANCER RESEARCH
- Role of microRNA in anticancer drug resistance
- (2009) Tongsen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
- (2009) A Davies et al. LEUKEMIA
- MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations
- (2009) Edurne San José-Enériz et al. Molecular Cancer
- Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia
- (2009) Gunhild Keller et al. Expert Review of Hematology
- A SNP in a let-7 microRNA Complementary Site in the KRAS 3' Untranslated Region Increases Non-Small Cell Lung Cancer Risk
- (2008) L. J. Chin et al. CANCER RESEARCH
- Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy
- (2008) J A McCubrey et al. LEUKEMIA
- Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells
- (2008) L L Remsing Rix et al. LEUKEMIA
- Regulation of ABCG2 Expression at the 3' Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line
- (2008) K. K. W. To et al. MOLECULAR AND CELLULAR BIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now